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Abstract In neurodegenerative diseases, cerebrospinal
ﬂuid analysis (CSF) is predominantly performed to exclude
inﬂammatory diseases and to perform a risk assessment in
dementive disorders by measurement of tau proteins and
amyloid beta peptides. However, large scale data on basic
ﬁndings of CSF routine parameters are generally lacking.
The objective of the study was to deﬁne a normal reference
spectrum of routine CSF parameters in neurodegenerative
diseases. Routine CSF parameters (white cell count, lactate
and albumin concentrations, CSF/serum quotients of
albumin (Qalb), IgG, IgA, IgM, and oligoclonal IgG bands
(OCB)) were retrospectively analyzed in an academic
research setting. A total of 765 patients (Alzheimer’s dis-
ease (AD), Parkinson’s disease (PD), Parkinson’s disease
dementia (PDD), vascular dementia (VD), frontotemporal
lobar degeneration (FTLD), progressive supranuclear palsy
(PSP), multisystem atrophy (MSA), motor neuron diseases
(MND), spinocerebellar ataxia (SCA), Huntington’s dis-
ease (HD)) and non-demented control groups including a
group of patients with muscular disorders (MD). The main
outcome measures included statistical analyses of routine
CSF parameters. Mildly elevated Qalb were found in a
small percentage of nearly all subgroups and in a higher
proportion of patients with PSP, MSA, VD, PDD, and
MND. With the exception of 1 MND patient, no intrathecal
Ig synthesis was observed. Isolated OCBs in CSF were
sometimes found in patients with neurodegenerative dis-
eases without elevated cell counts; lactate levels were
always normal. A slightly elevated Qalb was observed in a
subgroup of patients with neurodegenerative diseases and
does not exclude the diagnosis. Extensive elevation of
routine parameters is not characteristic and should
encourage a re-evaluation of the clinical diagnosis.
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Introduction
Neurodegenerative disorders represent a major health
problem that negatively affect the quality of life in our
aging society [23]. Until the early 1990s, neurochemical
laboratory diagnosis of neurodegenerative disorders pre-
dominantly concentrated on the exclusion of other
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origin. Nowadays, CSF analyses are also performed to
measure biomarkers associated with speciﬁc pathomecha-
nisms of the underlying neurodegenerative disease [33].
Nevertheless—prior to the application of more speciﬁc
CSF parameters—a routine work-up of basic CSF ﬁndings
should be performed [27]. So far, a large scale systematic
evaluation of routine CSF parameters including white cell
count, lactate concentration, CSF to serum ratios of albu-
min (Qalb), and immunoglobulins IgG, IgA, and IgM does
not exist. Furthermore, various studies on mostly smaller
cohorts of patients reported conﬂicting evidence with
regard to basic CSF ﬁndings. For example, Fro ¨hlich et al.
[8] detected a normal blood–CSF barrier function in Alz-
heimer’s disease (AD) and no evidence of an intrathecal
synthesis of IgG. In contrast, Hampel et al. isolated oli-
goclonal bands (OCB) in CSF in up to 20% of AD patients,
indicating a humoral immune response within the central
nervous system (CNS), accompanied by a blood–CSF
barrier dysfunction present in 16% of the cases. Likewise,
Zimmermann et al. [37] found intrathecal IgG synthesis in
some of their AD patients without identifying a satisfying
reason for the intrathecal humoral response. These ﬁndings
were conﬁrmed by Janssen et al. [14] who observed posi-
tive OCB not only in AD but also in other dementias,
including frontotemporal lobar degeneration (FTLD) and
Creutzfeldt–Jakob disease. In motor neuron diseases
(MND), elevated levels of CSF total protein, Qalb, and the
presence of intrathecally IgG synthesis were observed [3,
31].
Because of these scarce and inconsistent data, the goal
of this study was to analyze routine CSF parameters of a
large cohort of patients with different neurodegenerative
diseases to deﬁne a normal reference spectrum of routine
ﬁndings.
Materials and methods
Patients
Data from 765 patients collected by the neurochemical–
neuroimmunological laboratory, University of Ulm (Ger-
many) over 10 years (2000–2010) were respectively ana-
lyzed and included patients with clinically deﬁnite PDD,
PD, MSA with subgroups of the parkinsonian type (MSA-P)
and the cerebellar type (MSA-C), PSP, corticobasal
degeneration (CBD), spinocerebellar ataxia (SCA), MND
(including ALS, hereditary spastic paralysis (HSP), and
spinal muscular atrophy (SMA)), AD, VD, FTLD, Hun-
tington’s disease (HD), patients with muscular diseases
(MD) and control subjects with other (neurological) dis-
orders without signs of neurodegenerative diseases (CON,
including the diagnoses depression, dissociative disorders,
seizures, headache, polyneuropathy, transitoric ischemic
attack, and neuritis vestibularis).
CSF lumbar puncture was performed in all patients as
part of the routine neurological diagnostics, and all patients
have given their written informed consent.
The study was reviewed by the appropriate ethics
committee in Ulm (approval number: 20/10) and was
performed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki.
An overview of all CSF data of the 765 patients is given
in Table 1.
Analytical procedures
CSF was collected in polypropylene tubes and was
immediately analyzed regarding routine parameters within
1 hour after lumbar puncture. Determination of leukocyte
count was performed microscopically in a Fuchs–Rosen-
thal chamber [9]. CSF samples with contamination of
erythrocytes were excluded in order to avoid false positive
values of CSF albumin and lactate. Total protein, albumin,
IgG, IgA, and IgM were measured by standard immuno-
chemical nephelometry in CSF and serum (Dade–Behring
nephelometer analyzer, Marburg, Germany) using a poly-
clonal antibody in the case of albumin and IgG as well as a
latex particle-ampliﬁed antibody reaction in the cases of
IgA and IgM. The inter- and intra-assay variabilities were
\10% for the method-dependent absolute levels as well as
for the method-independent CSF/serum quotients of albu-
min, IgG, IgA, and IgM [25]. CSF lactate was determined
by a lactate–oxidase reaction (Greiner GmbH, Flacht,
Germany) and detection of oligoclonal bands was per-
formed by isoelectric focusing on agarose gels and sub-
sequent immunoblotting using an IgG-speciﬁc antibody
staining (Servalyte, Serva) [15]. In demented patients,
concentrations of tau and Abeta 1–42 were investigated.
Concentrations of CSF tau were determined using an
ELISA (Innotest hTAU-Ag; Innogenetics NV, Gent, Bel-
gium) constructed to measure both normal tau and phos-
phorylated tau (detection limit: 60 pg/ml) [35]. The
concentration of CSF Abeta 1–42 was determined by an
ELISA (Innotest Abeta 1–42; Innogenetics, Belgium)
speciﬁc for Abeta 1–42 (detection limit: 50 pg/ml) [1]. All
samples were run in duplicates and ELISAs were per-
formed as earlier described [18].
Evaluation of CSF parameters
Intrathecal synthesis of IgG, IgA, and IgM was detected
based on the method of Reiber referring the IgG, IgA, and
IgM quotients to Qalb, with a nonlinear reference range of
blood-derived proteins in CSF (see Fig. 1) based on the
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123physiologically and theoretically derived hyperbolic func-
tions [24, 26]. The data are presented to the clinician either
graphically in the diagrams by Reiber, so called Reiber-
grams (see Fig. 3) or numerically by calculation of the
intrathecally synthesized amount (Igloc) in mg/l CSF or as
the relative intrathecal fraction (IgIF) in % of the total Ig
CSF concentration. To ensure maximal sensitivity, the
interpretation of an intrathecal synthesis refers to the upper
border line of the reference range (Qlim in the quotient
diagrams). This line is based on Qmean ? 3s (or a reference
range including 99% of the noninﬂammatory cases). The
comparison of different patient groups in the nonlinear
evaluation diagrams needs the reference to the mean values
of the reference range in the Reibergrams (Qmean)a s
evaluated in the CSF statistics tool (‘‘Protein Statistics in
CSF Analysis with Reibergrams’’, Version 3.0, COMED).
Intrathecal Ig synthesis is calculated with Igloc in mg/l
replacing Qlim by Qmean.I g IF, the relative intrathecal
fraction is not useful for statistics of groups.Intrathecal Ig
synthesis with reference to Qmean is calculated according
to:
Igloc mean ðÞ ¼ QIg   QIg mean ðÞ

  Ig serum mg=l ½  :
Statistics
Assessment of the mean quantity and frequency of intra-
thecal Ig synthesis, frequency of blood–CSF barrier dys-
function and Reibergrams were determined using the
software ‘‘Protein Statistics in CSF Analysis with Reiber-
grams’’ (Version 3.0, COMED), which calculates quotients
and the intrathecally synthesized fractions [IgXloc (m) or
IgXIF (m)] with reference to the Qmean of the reference
range. The age-related reference range of Qalb was calcu-
lated as Qalb = (4 ? age/15) 9 10
-3 [29]. The calculated
Table 1 Illustration of additional laboratory parameters, including CSF white cell count, CSF lactate, CSF tau and Abeta (Ab) 1–42, isolated
oligoclonal IgG bands (OCB) in CSF, as well as the diagnostic criteria (DC) for all groups investigated
Disease N Age ± SD Age related Qalb Leukocyte count/ll Lactate OCB Tau in pg/ml Ab in pg/ml DC
PDD 25 71 ± 10 8.7 0.64 ± 0.76 1.72 ± 0.36 0 272 ± 172 725 ± 287 [7]
PD 47 66 ± 11 8.4 0.89 ± 1.45 1.73 ± 0.34 0 296 ± 290 967 ± 312 [20]
MSA-P 12 64 ± 9 8.3 1.83 ± 3.18 1.58 ± 0.13 0 239 ± 101 755 ± 105 [10]
MSA-C 13 65 ± 9 8.3 1.15 ± 1.21 1.72 ± 0.33 0 221 ± 74 794 ± 250 [10]
PSP 16 69 ± 7 8.6 0.75 ± 1.32 1.79 ± 0.35 0 244 ± 133 636 ± 305 [19]
CBD 5 69 ± 9 8.6 0.80 ± 0.84 1.59 ± 0.17 0 221 ± 91 904 ± 282 [6]
SCA 6 61 ± 12 8.1 0.83 ± 0.41 1.72 ± 0.29 0 208 ± 79 916 ± 214 [16]
MND 177 62 ± 14 8.1 1.02 ± 1.13 1.75 ± 0.23 1 289 ± 259 924 ± 305 [32]
AD 289 72 ± 8 8.8 0.73 ± 2.10 1.76 ± 0.31 3 667 ± 405 534 ± 277 [21]
FTLD 28 68 ± 9 8.5 0.50 ± 0.74 1.73 ± 0.23 0 467 ± 318 672 ± 233 [22]
VD 13 71 ± 8 8.7 1.00 ± 0.71 1.84 ± 0.14 0 275 ± 153 683 ± 162 [36]
HD 31 55 ± 18 7.7 1.19 ± 1.70 1.59 ± 0.39 0 – – [13]
MD 20 57 ± 20 7.8 3.00 ± 9.50 1.70 ± 0.60 1 – – –
CON 83 53 ± 18 7.5 1.28 ± 2.92 1.73 ± 0.34 0 – – –
PDD Parkinson disease dementia, PD Parkinson disease, MSA-P/C multisystem atrophy with Parkinson/cerebellar syndrome, PSP progressive
supranuclear palsy, CBD corticobasal degeneration, SCA spinocerebellar atrophy, MND motorneuron disease, AD Alzheimer disease, FTLD
frontotemporal lobar degeneration, VD vascular dementia, HD Huntington disease, MD muscle disease, CON control group
Fig. 1 CSF–serum quotient diagram for IgG with hyperbolic refer-
ence range according to Reiber [24]. On the abscissa, a Qalb of 1
represents a normal blood–CSF barrier function; 2 demonstrated a
blood–CSF barrier dysfunction. The ordinate demonstrates QIgG with
the upper limit for Qlim, Qmean, and Qlow, whereby values below Qlim
can discriminate the blood-derived IgG fraction from an intrathecal Ig
synthesis either represented by 4 as intrathecally IgG synthesis only
or as 3 demonstrating a combined blood–CSF barrier function
together with an intrathecal IgG-synthesis. 5 is not possible and
indicates a methodological error in the measurement
1036 J Neurol (2011) 258:1034–1041
123upper limit of the reference range of Qalb is also a function
of the volume of CSF extraction. To allow a modiﬁcation
of the decision cutoff in cases of unknown volumes of
extraction, we refer to two different levels, a 10% and a
20% level. The 20% level [Qalb = (4 ? age/15) 9
10
-3 9 1.2] is best for small extraction volumes to
increase the reliability of an interpretation as a blood–CSF
barrier dysfunction; thus, the statistical analysis was per-
formed on that basis because the exact CSF volumes of all
samples could not retrospectively be identiﬁed.
To test the signiﬁcance of the difference between the
calculated means and the mean of the noninﬂammatory
control group, we used the program available at http://
daten-consult.de/forms/ttestunabh.html. The control group
is represented by 4,300 patients without a humoral immune
response in the CSF [24]. The investigation of the smaller
CON group in our laboratory was performed as an internal
control, but all statistical analyzes are related to the control
group of reference [24], which is the basis of statistical
examinations in the software program. P values below 0.05
are considered signiﬁcant.
Results
Frequency and extent of intrathecal Ig synthesis
and OCB
In AD, intrathecal Ig synthesis of IgA and IgM were found
in 2 and 3 cases, respectively, with positive OCB. Addi-
tional analyses including PCR and antibody indices (AI)
for Borrelia burgdorferi showed negative results and
because Igloc (mean) was also negative, statistical analyses
were not performed. Intrathecal IgM synthesis in 2 patients
with PDD was accompanied by negative OCB and normal
white cell counts. Thus, because the Igloc (mean) was
positive, statistical analysis was performed with a nonsig-
niﬁcant p value of 0.851. In 2 MND patients having
intrathecal Ig synthesis of IgG and IgA, respectively,
accompanied by positive OCB, Igloc (mean) was negative;
thus, statistical analysis was renounced. As Igloc (mean)
was negative for IgG, IgA, and IgM in the other patient
groups, the calculation of mean values of IgXIF (m) was not
reasonable due to the fact that negative values are not
possible by deﬁnition and a statistical evaluation is not
possible in cases of a negative IgXloc (m). For detailed
information see Online Resource Table 1.
Frequencies of blood–CSF barrier dysfunction
In relation to the age-matched Qalb, elevated Qalb values
with an increase of C25% were detected in PSP and MSA-
P in 23% of the patients in VD, in 20% of the patients in
PDD, and in 46% of the cases of MSA-C (see Online
Resource Table 2).
Outliers of CSF–blood barrier dysfunction
Concerning dysfunction of the CSF–blood barrier, reasons
for all outliers were detected. Here, osteodegenerative
diseases with stenosis of the spinal canal could often traced
back to the herniation of a lumbar intervertebral disk or to a
scoliosis as a frequent cause for elevated Qalb values (as
seen in 1 PD patient, 1 patient among the persons with
MSA-P, 2 patients in the MSA-C group, 2 AD patients as
well as in 1 PDD patient, 1 HD diseased person, 1 MD
patient, and 1 patient of the CON group). Besides degen-
erative processes of the spine, metabolic dysfunctions
related to insufﬁciently treated diabetes with severe dia-
betic vasculo- and neuropathy were additional causes for
the elevated QAlbvalues as detected in 1 FTLD patient. For
detailed information, see Fig. 2 and Online Resource
Table 2.
Lactate levels and white cell count
Reference values of L-lactate are age-dependent (mmol/l
= mg/dl 9 0.11):
0–15 years: 1.1–1.8 mmol/l (9.9–16.2 mg/dl)
16–50 years: 1.5–2.1 mmol/l (13.5–18.9 mg/dl)
[51 years: 1.7–2.6 mml/l (15.3–23.4 mg/dl)
Fig. 2 Illustration of age-related Qalb. CSF–blood barrier (dys-)
function of all groups are indicated on the basis of Qdiff that represents
the age-dependant CSF–blood barrier function according to Qdiff =
Qalb - Qalb* (with Qalb* = (4 ? age in years)/15) 9 10
-3). The box
represents the 25th to 75th quartile, whiskers represent the range, the
vertical line in the boxes shows the median and circles depict outliers.
The numbers of patients correspond to the numbers given in Table 1
J Neurol (2011) 258:1034–1041 1037
123No elevated lactate levels were detected in any of the
groups investigated. Regarding leukocyte counts, 1 patient
of the MD group had an increased level of 43 leukocytes/ll
traced back to a reactive pleocytosis in the scope of sep-
ticemia by phlegmon.
Data are summarized in Table 1.
Reibergrams
The CSF–serum albumin concentration quotient is gener-
ally accepted as the best indicator to characterize the
blood–CSF barrier function for blood-derived proteins in
the CSF; this is due to the fact that albumin in CSF
exclusively originates from blood. In case of pathological
changes, Qalb is the most relevant parameter to indicate a
change in blood–CSF barrier function. This quality of Qalb
led to the development of quotient diagrams in which the
immunoglobulin quotients are referred to the albumin
quotient, a model that allows quantiﬁcation of an intra-
thecal protein fraction independent of the individual blood–
barrier function. Former methods to measure the intrathecal
IgG synthesis according to Delpech–Lichtblau (IgG index)
or Tourtellotte are based on a linear CSF–blood ﬂow and
are associated with false-positive values for intrathecal IgG
(with higher errors for IgA and IgM) in cases of high Qalb.
The model of Reiber [24] for the blood–CSF barrier
function describes a diffusion system where on one side of
a restricted range (tissue) is the solute (blood) and at the
other side a solvent (CSF) which is the source of a steady
elimination process by the ﬂowing CSF in a hyperbolic,
nonlinear range.
The graphic representation of the Reibergrams allows a
direct visual interpretation of the data (see Fig. 1). Values
above Qlim (for the individual patient) or Qmean (for a group
of patients), respectively, indicate the intrathecal fraction
of a protein (IgG, IgA, and IgM) in % (whereby Qlim/Qmean
represent 0%). The limit for Qalb as a measure for the
CSF–blood barrier function is age-dependant according to
Qalb = (4 ? age in years)/15) 9 10
-3.
Figure 3 illustrates the Reibergrams that use the asso-
ciated IgG, IgA, and IgM diagrams depicted horizontally
for better pattern recognition among the different patient
groups, especially when the variability of Qalb is
considered.
Discussion
CSF routine parameters are an integral part of the diag-
nostic procedure in neurodegenerative diseases and form
the basis for further disease-speciﬁc examinations. For this
reason, they have been included in the guidelines for
dementia diagnostics by the German societies for
psychiatry and neurology [5]. To give an overview of what
comprises the normal reference spectrum, to decide in
which cases examination of special parameters is indicated,
and to consider when it is necessary to re-evaluate the
preliminary diagnosis, and reﬂect on possible alternative
mechanisms as a reason for the pathological values, we
retrospectively analyzed routine CSF data collected in our
neurochemistry laboratory.
Intrathecal Ig synthesis and OCB
In contrast to chronic inﬂammatory diseases of the CNS
[28], we observed mild intrathecal Ig synthesis in only a
few cases, which could be either traced back to a former
infection of the CNS or to an immune process in a sub-
fraction of patients with neurodegenerative diseases [11].
Because leukocyte counts and lactate levels were normal in
those cases, we favor the explanation of an immunological
scar due to a former infection. Highly elevated Ig values as
indicators of an inﬂammatory process are not representa-
tive and should lead to a re-evaluation of the data by
repeated investigations to exclude false-positive measure-
ments and in cases of conﬁrmed elevated values, to the
investigation of special parameters (PCR or antigen spe-
ciﬁc antibodies). This is important for those cases where an
early infection of the CNS is presented by intrathecal Ig
synthesis with negative OCB [4, 12] and should lead to re-
evaluation of the neurodegenerative diagnosis, whereby the
seldom simultaneously occurrence of a neurodegenerative
and an inﬂammatory disease has to be taken into account.
Blood–CSF barrier dysfunction
Dysfunction of the CSF–blood barrier is present in various
neurological diseases of inﬂammatory and noninﬂamma-
tory etiology and may even be found in patients with no
neurological diseases [3]. We and others [17] observed
elevated frequencies of Qalb between 25 and 45% in PSP
and MSA, possibly due back to an age-related effect with a
reduction of the CSF ﬂow, an increased prevalence of os-
teodegenerative diseases of the spine, or metabolic dys-
functions, such as diabetes or obesity. In accordance with
previous ﬁndings [3, 11], we found CSF–blood barrier
dysfunctions with frequencies of 20–25% in PDD and VD,
whereby dysfunction of endothelial cells with increased
permeability of serum proteins was hypothesized in VD as
a pathophysiological explanation [30]. Regarding the sub-
group of MND patients, we and others found elevated
levels of CSF total protein associated with a slightly
impaired CSF–blood barrier dysfunction [2, 31]. In GBS
and CIDP, reduction of the CSF ﬂow rate traced back to an
inﬂammatory swelling in the region of the spinal roots as
possibly being a reason for the QAlb elevation [34]. Similar
1038 J Neurol (2011) 258:1034–1041
123Fig. 3 Illustration of Reibergrams for all patient groups. Q–IgG, Q–IgA, and Q–IgM are indicated in relation to the CSF–blood barrier function,
represented by Qalb. For interpretation of the Reibergrams, see Fig. 1
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for CSF–blood barrier dysfunction, where structural alter-
ations of the anterior nerve roots may be responsible for
reduction of CSF –ﬂow rate. So that in all cases with highly
elevated QAlb, alternative reasons should be excluded, e.g.,
metabolic as well as myelostenotic processes being the
most frequent.
White cell count and lactate levels
Among the patients investigated, only 1 case with MD
showed elevated white cell count due to a coincidental
systemic infection, so that elevation of leukocyte count and
lactate levels are primarily not compatible with the diag-
nosis of neurodegenerative diseases and should lead to
investigation of alternative reasons. In addition, an increase
of both parameters may be helpful in cases with intrathecal
Ig synthesis to exclude or conﬁrm inﬂammatory processes
and may support the decision whether additional CSF
parameters should be investigated.
Comprehensive, CSF routine parameters are necessary
to exclude other nonneurodegenerative diseases and should
be introduced into neurochemical laboratories. Slight ele-
vation of QAlb and mild intrathecal Ig synthesis seem to be
nonspeciﬁc ﬁndings in these disorders and do not exclude
the diagnosis. However, highly pathological values of
routine parameters were not observed and are suggestive
for other diseases or alternative mechanisms if a neurode-
generative disease is still supposed.
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